OPKO Health, Inc. Our History WHO WE ARE Timeline 2007 March 2007 The ophthalmic pharmaceutical companies Acuity Pharmaceuticals and the Froptix Corporation merge with eXegenics Inc. to form OPKO Health. 2009 October 2009 OPKO acquires the Chilean pharmaceutical distributor Pharma Genexx S.A., which marks the beginning of OPKO's Latin American presence. 2010 February 2010 OPKO acquires Mexican drug manufacturer and distributor Pharmacos Exakta, S.A. de C.V December 2010 OPKO and TESARO, Inc. sign an exclusive license agreement for the development and marketing of the oncology support drug, Rolapitant® 2011 September 2011 OPKO agrees to sell its ophthalmic instrumentation business to OPTOS, Inc. October 2011 OPKO acquires microfluidics based diagnostic test system developer, Claros Diagnostics. December 2011 OPKO acquires FineTech Pharmaceutical Ltd., an Israeli company which develops and produces high value, high potency active pharmaceutical ingredients (APIs). 2012 January 2012 OPKO acquires the rights to a kallikrein based prostate cancer diagnosis test from Arctic Partners Ab Oy. This test would become a key component of OPKO's 4Kscore® prostate cancer risk assessment laboratory developed test. August 2012 OPKO acquires Spanish pharmaceutical, nutraceutical and veterinary product company, Farmadiet Group Holding, S.L. 2013 January 2013 OPKO acquires Cytochroma Inc. and their lead nephrology products, Rayaldee® (calcifediol) and Alpharen®. August 2013 OPKO acquires PROLOR Biotech, with platform technologies to extend the biological half-life of therapeutic proteins and peptides. This technology is used in OPKO's late clinical stage product Somatrogon©, for the treatment of growth hormone deficiency (GHD), and in a Factor VIIa product for the treatment of hemophilia A & B. 2014 March 2014 OPKO launches the 4Kscore® test in the United States (U.S). The 4Kscore® test is a laboratory developed test and is suggested to be used after an elevated prostate specific antigen (PSA) test result to risk stratify the detection of aggressive prostate cancer. May 2014 OPKO presents data demonstrating that the 4Kscore® is an accurate, sensitive, and personalized predictor of high-grade prostate cancer at the American Urological Association Plenary Session. September 2014 OPKO launches the 4Kscore® test in Europe. December 2014 OPKO and Pfizer Inc. enter into a strategic partnership for the development and commercialization of OPKO’s long-acting human growth hormone, Somatrogon©. 2015 May 2015 OPKO acquires EirGen Pharma (Eirgen), Ireland. EirGen specializes in the development and manufacturing of high potency pharmaceutical products. August 2015 OPKO acquires the full service clinical laboratory, BioReference Laboratories, Inc. December 2015 OPKO subsidiary GeneDx demonstrates that whole exome sequencing can provide a definitive diagnosis for patients with rare and complex genetic conditions. 2016 May 2016 OPKO and Vifor Fresenius Medical Care Renal Pharma entered into a collaboration and license agreement for the development and commercialization of Rayaldee® (calcifediol) in Europe, Canada, Mexico, Australia, South Korea and other international markets for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) and vitamin D insufficiency. June 2016 The U.S Food and Drug Administration (FDA) approves a New Drug Application (NDA) for Rayaldee® (calcifediol) extended release capsules for the treatment of SHPT in adults with stage 3 or 4 CKD and vitamin D insufficiency, defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL. August 2016 OPKO acquires the Canadian biopharmaceutical company Transitions Therapeutics Inc. and its products in clinical development. October 2016 OPKO enters into the animal health market with the launch of its line of U.S veterinary pharmaceuticals and nutraceuticals. November 2016 OPKO announces the U.S launch of Rayaldee® (calcifediol). 2017 October 2017 OPKO enters into an exclusive agreement with Japan Tobacco Inc. (JT) for the development and commercialization of Rayaldee® in Japan. 2018 July 2018 OPKO's strategic partner Vifor Fresenius receives marketing approval for Rayaldee® in Canada. 2019 January 2019 OPKO announces FDA approval for the point-of-care Sangia PSA Test with the Claros® 1 Analyzer. © 2021 OPKO Health, Inc. All Rights Reserved. PRIVACY POLICY GOVERNANCE TERMS OF USE SITEMAP